Post by
canadafan on Nov 11, 2024 6:53pm
worth repeating
My compliments to notale, for vwery concise recap of ONCs bio, vs anoher company with much less trading at $2.8 billion.
Im repostng this , as far more important than any drivel, other backgound drivel
Thanks for the hard work notable.
.So let's get back to the facts of the matter. CGON has one indication in late stage clinical trials and has a market cap of US$2.7 Billion.
ONCY has 5 indications that are Phase 2/3 / Accelerated Approval ready.
This is particularly threatenting to those others who are supporting other oncolytic virus companies and who post smack on this message board.
These 5 indications with pelareorep are:
(1) HR+/HER2 negative metastatic breast cancer;
(2) Triple Negative Breast Cancer (TNBC);
(3) pancreatic cancer with pelareorep + ICI + n-paclitaxel;
(4) pancreatic cancer with pelareorep + ICI + folfirinox, and;
(5) anal (SCCA) cancers.
Furthermore, ONCY needs to update its shareholders that pelareorep is effective as a single dose in the treatment of Hepatocellular carcinoma cancer (HCC), as recently demonstrated in an updated paper.
https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=34674668
https://www.medrxiv.org/content/10.1101/2024.09.26.24314049v
Comment by
Buckhenry on Nov 11, 2024 8:53pm
Canuckcluck et al... has been posting this same ole stuff fir the last 5 years saying the buyout is eminent... crying wolf... no one believes you girls now... maybe something will happen but it won't be because of what you clucks have been posting on here forever and ever.
Comment by
Buckhenry on Nov 11, 2024 10:16pm
I just love all the pumpers posts.... right up to the point nothing happens but they swear its eminent.